je

DILS





:
: . ,
e

:
: ,
1.000
ISBN 978-86-83607-82-2

CIP -
,
616.892.3(083.1)

/
[]
,
; [
]. - :
, 2013 ( :
). - 36 . : ; 30 cm. - ( ; #18,
#2013)
1.000. - . 3: /
. - : .
4. - : . 36.
ISBN 978-86-83607-82-2
1. . .


a) -
COBISS.SR-ID 203036940


,
. a
.
, , .

,
.
DILS 2013.
, ,
.
, , .
,
,
.
, .
, , p
: . , . , . , . , . , . , . , . , .
, . , . , , .
. . .


, .

, ,

.
, , - ,
.
, .
,
,
.
,
,
.

(. NICE SIGN ).

,
.
, ;
.


: , .
( )
: . ( )
:
( ):
/

I:
II:

IIa: /

ee II b:

III:

IV: ,
:

:
.
, , , , ,

:
. .
, , ,
:
.
, , ,
,
.
, ,
,
.
, ,
.
,

, , ,
. .
, , ,


, ,
. .
,
, ,

, ,
,
6

:
.
, ,
.
,
.
,
, ,


...................................................................................................................................................... 11
1. , ........................................................................ 11
2.  () . ................................... 17
3. 
. .................................. 25
4.  ,
. ........................................................... 28
5.  .................................. 33
6.  :
........................................................................... 34
7. ......................................... 34

10


A () . , , , .
, ,
;
, .
610% 65. .
(6070%) , : (), () .
( 2011. ), 17,7% 65 ,
.

,
. .
(2,5 5%).
,

.

1. ,
1.1. ()
() : )
(, ); )
, ,
. , 1.
( = 1,90 95% CI 1, 552,33), , ( 1,59 95% CI 1, 351,86), ( 1,82 95% CI 1,192,78) ( NICE Guideline, 2007).
1.

(95% CI)

: 1,61 (1,161,24)

: 1,39 (1,171,66)

: 1,60 (1,341,92)
: 1,50 (1,161,94)
: 1,59 (1,152,20)

11

:
. ( 65 69 1,2:1 , 70 85
1,6:1 , 85 2:1 );
.
, 2,5 5% ( ),
.
, .
1, 2 (PS-2) 13 ;
14, 1 (PS-1) 185
21, 33 .
, 1525% , ; .
(APO) 19. ,
( P-4 1011 ,
) ( NICE Guideline, 2007). , GWS
REM2,
Clusterin (CLU) , Phosphatidylinositol-binding clathrin assembly protein (PICALM) , Complement
receptor 1 (CR1) , ATP-binding cassette sub-family A member 7 gene (ABCA7), Membrane-spanning
gene cluster (MS4A6A/MS4A4E), Ephrin receptor A1 (EPHA1), CD33, CD2AP (Guerreiro NEJM 2013;
(368)2; Neumann NEJM 2013).
:

, , , . ,
. (
), , 75 , (Friedland Nandi, 2013).

, ( 2).
2. ( Gorelick, 2011)

SHEP

16% ;

Syst-Eur

50% (076%) ;
p = 0,05

23 7

PROGRESS

12% (- 8% 28%)
; p = 0,2

34% (3% 55%)

; p = 0,03
1% (- 24% 22%) ; p = 0,9

SCOPE

7% ; p > 0,20

HYVET

14% (- 9% 23%)
; p = 0,2

(164 )
(84 )

PRoFESS

;
p = 0,48
;

12


() , ,
OR 1,2 (CI 95% = 1,051,4) (
3) (Friedland Nandi, 2013).
. , 2, ,
(yuex, 2012).
,
.
3.
a

Peila, 2002.

77

; RR (95% CI)1,7 (1,02,8)

Yamada, 2003.

43

; RR 4,4

Akomolafe, 2006-

70

;
RR (95% CI) 2,98 (1,068,9)

Ott, 1999.

69

; RR (95% CI) 1,9 (1,23,1)

Luchsinger, 2001.

76

; RR (95% CI) 2,4 (1,83,2)

RR (95% CI) 2,0 (1,42,9)

Arvanitakis, 2005.

75

; RR (95% CI) 1,7 (1,12,5)

Xu, 2004.

81

; RR (95% CI) 1,3 (0,81,9)

RR (95% CI) 1,3 (0,92,1)

Luchsinher, 2005.

76

; RR (95% CI) 2,4 (1,83,2)

RR (95% CI) 2,0 (1,42,9)

Curb, 1999.

53

; RR (95% CI) 1,0 (0,52,0)

Hassing, 2002.

84

; RR (95% CI) 0,8 (0,51,5)

MacKnight, 2002.

74

; RR (95% CI) 1,2 (0,81,8)

RR (95% CI) 1,3 (0,82,0)

.
( 4). ,
.

13

4. (
Duron Hannon, 2008)
a

Notkola, 1998.

4059

; RR (95% CI)
3,1 (1,28,5)

Kivipelto, 2002.

53

; RR (95% CI)
2,8 (1,26,7)

Moroney, 1999.

75

LDL ;
RR (95% CI) 3,1 (1,56,1)

Kalmijn, 2000.

52,7

;
RR (95% CI) 1,10 (0,951,26)

Tan, 2003.

76

;
RR (95% CI) 0,97 (0,901,05)

Reitz, 2004.

78

LDL ; RR (95%
CI) 0,48 (0,260,86)

Mielke, 2005.

70

;
RR (95% CI) 1,3 (0,81,9)
RR (95% CI) 0,31 (0,110,85)

6073%
, (Duron
Hannon, 2008). , ( 5).
5. ( Shepardson, 2011)
a

Felman, 2010.

Friedhoff, 2001.

Heart Protection Study Collaborative Group, 2002.

Shepard (PROSPER), 2002.

Sparks, 2005.

(HR 1,39; 95% CI = 1,031,87). (HR 0,63; 95% CI = 0,440,91), (1,62; 95% CI = 1,022,64). (Barnes Yaffe, 2013).

13
: 7 - RR 2,01; 95% CI 1,163,50 RR 1,87; 95% CI 1,093,20
(Barnes Yaffe, 2013). 20
102.172 : 9 - R 2,03 (95% CI
1,732,38) 11 R 1,90 (95% CI 1,552,33). (Barnes Yaffe, 2013).

, 14

 .
.
(, .). (
.)

, ( 1,161,79).
.


P-4 .

1.2.
( , , ,
, , , )
.
, (HR 0,39) ,
.
, , , , ( ), , ,
, , .

( : 1, 6, 12; , , )
,
.

, 11 .

( 20 30
) ( NICE Guideline, 2007).
(Mayeux Stern, 2012).

15

6. ( Mayeux Stern,2012)

( . )

II

II

,
, , 2, .

1.3.

, .

(Snitz
., 2009).
(Deosky ., 2009; Vellas ., 2012). , , , , .

1.4.
8.
( Albert ., 2011) ()
(8) ()
16 .

, ,
.
, .
,
, .
, .

10 20%
65 .
, 5 10% (12% ),
10 15% ,
16

 , 12 %. 4550%
.
.
, , ,
, .
,
. () ,
, , ( 7).
7. ,

/

/

2.
( ) ( ) (
Albert ., 2011).

2.1.
1. , ,
;
2.
; ;
3. (. , ).

;
4.
. .

.

2.2.
.
1 1,5
17

( ). ,
.
2.2.1.
,

, , . Freeand Cued Selective Reminding Test (FCSRT),
Ry Auditory Verbal Learning est (RAVLT), California Verbal Learning Test (CVLT), Logical Memory
IandII, Visual Reproduction Subtest Wechsler Memory Scale/Revised.
, , , .
,
(. , . 14, , , . , , , ) .
, . ,
.
je .

2.3.
,
, :
(); ; .
o ,
, .
- (
, 1, 2), .
,
4 ,
. 4
, .
8. (
Albert ., 2011)

1.  (
)
2. 
, /

3.
4.
5.
6. , ,
7. ,
8. , .

18

 .
.

2.4.
(
),
. : )
- (-
-, - ); )
( ,
(),
- Single Photon Emission Computed Tomography (SPECT)
, .
( 9)
1.
- ;
.
2.
) -
;
) - .

. .
3. 
,
; .
4. 
, - . : ) , ; )
DAT SCAN : ) G-, DWI
MRI
(
6 ) ; ) , ,
.
,
.
, ,
.

, .
, ,
19

2.5.

1.
.
.
.
2. , , , ( EFNS
Guidelines, Hort, 2010).
3. ,
.
4.
1984.
81% 70%.
. ,
( McKhann, 2011):
1. ,
.
2.
(, , ).
3. , , .
4. , .
5. - , 1, 2, .
6. 40 . 90 .
7. , , .
( McKhann,
2011):
, .
()
:
1.  ();
2. ;
3. ;
4. : 1)
20

 ; 2) .
;
5. :
) ; :
, , ,
;
) , ; : , , , ;
) ; : , , ;
) (, , ); :
, , ;
) ; : , , ,
, , , , .
, .
o .

,
.
1. : :
1.1. :
. ,
;
. ;
. , , :
) : , .

;
) :
: , ;
: , , () .
;
: , .
. :
) ,
;
21

;
)  ;
) ;
)  / ;
)  , .


:
.

( , 1, 2), .
4 , .
:

,
,
.

:
a)  ,
;
(
);
b)  ;
c) 
.

-: 42
( 9).
: ( ); , , . .
, .
:
1) 
;
2) .

22

 ,
.

1)

, .
2)  ,
.
( 9).
,

( 9).
9. ( )

- (

( ,
, )

(
),

(
)

.
:
1) ;
23

2) ,
, ,
, ;
3) , .
A
:
/
( ).
 : TSH, fT4, 12, ,
.
.
, . FDG PET SPECT , ,
65. . DAT scan .
, , ,
- ,
65. ( ).


.

(), (-), , , .
: , 14, , ), ( 10).
, :
24/30,
27/30 ,
21 19

10.

?
?
/?
?
?
?

:

?

() - () ,
.
, , .
24


, ( , 1 2, ).
( 4 )
, .
.

, ; , ()
( EFNS Guidelines, Hort, 2010).

3.
!
.
75% .

3.1.

, ,
. ( ),
( EFNS Guidelines, Hort, 2010).

(, , )

. , ;
.
,
( 16 26).
- (
). (
), .
(<10).
Cochrane Review (2006) ,
.
. ( ) ,
; ,
. .
5 .
10
, .
, , , , . ,
.
25

2 1,5
1,5 . 612 , , a
. 4,6- , 9,5-
. ,
. .
8 , , 16 , .
24
.
, :
1. ;
2. ; 45 ;
3. 4070% ;
4.
.

, , -- () . 5
, 5
20 . , ,
, . .

, ; .

, ,
, e ( ) ( EFNS Guidelines, Hort, 2010).
7 (, , , , ) 1025% (1,13 ).

Alzheimer Society- 2004. , 4.000

(, ),

.

26

 ( EFNS Guidelines,

Hort, 2010)
1. , ,

.
. 3 4.
2. :
.
;
. .
3. :
.  (,
);
.  , ,
.
4. , ,
, ,
, .
5. , .

- 6.000
( 2.548 ,
380 )
, ,
, .
:
1. , .
2. , , .
3.
.
. , ,

.
. (),
.
) ,
, ;
) ,
.
4. , -,
.

( EFNS Guidelines, Hort, 2010)
: , , , ( 12 ), , , , , 27

, , ,
.

(Snitz ., 2009). (Deosky .,
2009; Vellas ., 2012). , ,
, , . ,
: , , , , ,
, 12 .

4. 

4.1. ()
()
8090% , , . ( , , ), , , ,
, , , , . , ,
, ( ) ( APA Guideline, 2007; BCMA Guideline, 2008).
,
.
, .

, ( BCMA Guideline, 2008).
, , ,
, , ,
.
: , , , , , , ,
, , .

:
:
(, , );
: ,
, , . ,
.
.

28


.
, , .
.

.
e , , .
, , ,
, . , , .
,
.
, , . , ,
( , , , ) ( NICE Guideline, 2007).

, , , .
(NICE Guideline, 2007).
, , , ,
, , , .

. , .

.
( , ),
( ).
(, , )
.
, ,
, ,
( BCMA
Guidelin, 2008). ( ), , ,
( PA Guideline, 2007).
, ,
. , .
, .
, . , (
NICE Guideline, 2007).
29

,
, ( BCMA, 2008).

4.2.
, , . ,
. -j .
, , , ,
.
, ,
.
. , (SSRI)
,
. SSRI . : , , , , , , ( 11).
SSRI, , .
, 5HT2A/ ,
( 25 50 200 ).
. ,
.
11.

(/)

(/)

10
25
10
10
5

1040
25200
1040
1040
520

150
7,5
37,5

300
1545
75225

4.3.

, ,
. . 50%
. .

,
, .
30

 , , .
SSRI . , . 12.
12.

(/)

(/)

5
3
4,6
8
150

2,55

10
12
9,5
24
300

20

( )
SSRI

,
, . , ,
, ,
, , (. , ). (, , , ,
) ( 0,5 1 46 13
, 0,25 0,5 , 12 ), . 0,5 2 . ,
,
( BCMA Guideline, 2008; APA Guideline, 2007).

50% , , .
. /
, (
0,25 2 ), ( 2,510 ), ( 25 )
( 200 ).
. ( APA Guideline, 2007), ,

, . , 13 ,
, , , .
,
.
/
: ) ()
( , , , , ), (, , , , 31

, ) ) , (,
, , , ,
), (, , ). , , ,
. , , , ; . ,
, , ,
( 13). ,
, , , ( 13).

( , ),
, . , . , , , .
.
. , .
,

(. ), ( 0,5
1 46 13 ), ( 0,5 2 ).
50 100 ,
, 600 800
. , SSRI
, ( APA Guidelines, 2007).
13.

0,250,5 (12 x)

0,25 37

1 2

2,55 (1 x)

2,55 37

7,510

2550 (2 x)

50 2 a 37

200

25

25 37

10

0,250,5 (12 x)

0,25 37

1 2

( , ), .

4.4.
2550% ,
( , ,
, ), , (
.) , .
, , ,
, .
32


, , ,
( APA Guideline, 2007).
, ( ),
. (25100 ), (510
), (510 ) (0,51 ).
( APA Guideline, 2007).

5.
.
, .
,

. .
1.1. 
.
1.2. 
, .
1.3.  , ( 10)
:
) ;
) , ;
) ;
) : , , , ;
) ,
, ;
) : , , ,
, , , , , o .
1.4.  . ,
, ,
.
1.5. , o , , , , , , , . .
1.6.  .

33

6.  :

, a , ,
.
,
, , .

, , , .
, , , , , , .

, , ,
,
, , e , e
( NICE Guideline, 2007).
, . , (
)
.
,
( ,
20 ).
,
,
( NICE Guideline, 2007).
,

, .
,


.

7. 

, , .
:
.
34

 e
(. ).
, /
- .
.
1.
,
.
2. ,
.
3. ,
, .
4. .
5. .

35

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive
impairment due to Alzheimers disease: recommendations from the National Institute on Aging-Alzheimers
Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 2011;7(3):270-9.
2. APA Work Group on Alzheimers Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, Rummans T,
Schneider LS, Tariot PN, Blass DM. American Psychiatric Association practice guideline for the treatment of patients
with Alzheimers disease and other dementias. Second edition. Am J Psychiatry. 2007 Dec;164(12 Suppl):5-56.
3. Barnes De, Yaffe K. The projected impact of risk factor reduction on Alzheimers disease prevalence. Lancet Neurol
2011;10(9):819-828.
4. Cognitive Impairment in the Elderly Recognition, Diagnosis and Management. Guidelines and Protocols. British
Columbia Medical Association (BCMA), Revised 2008.
5. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, et al; Ginkgo Evaluation of
Memory (GEM) Study Investigators. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA
2008;300(19):2253-62
6. Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag 2008;4(2):363-81.
7. Friedland RP, Nandi S. A modest proposal for a longitudinal study of dementia prevention (with apologies to Jonathan
Swift, 1729). J Alz Disease 2013;33:313-315.
8. Gorelick PB, Scuteri A, Black SE, et al. Vascular Contribution to Cognitive Impairment and Dementia: A Statement for
Health Professionals From the American Heart Association/American Stroke Association. Stroke 2011;42:2672-2713.
9. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, etal; Alzheimer Genetic Analysis Group.
TREM2 variants in Alzheimers disease. N Engl J Med 2013;368(2):117-27.
10. Hort J, OBrien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P; EFNS Scientist Panel on
Dementia. EFNS guidelines for the diagnosis and management of Alzheimers disease. Eur J Neurol 2010;17(10):1236-48.
11. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly
JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH.The
diagnosis of dementia due to Alzheimers disease: recommendations from the National Institute on Aging-Alzheimers
Association workgroups on diagnostic guidelines for Alzheimers disease.Alzheimers Dement2011;7(3):263-9.
12. Mayeux R, Stern Y. Epidemiology of Alzhemier Disease. Cold Spring Harb Perspect Med 2012; doi: 10.1101/
cshperspect.a006239.
13. National Collaborating Centre for Mental Health (UK). Dementia: A NICE-SCIE Guideline on Supporting People
With Dementia and Their Carers in Health and Social Care. Leicester (UK): British Psychological Society; 2007.
14. Neumann H, Daly MJ. Variant TREM2 as risk factor for Alzheimers disease. N Engl J Med 2013;368(2):182-4. J
Alzheimers Dis 2013;33(2):313-5.
15. Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol and Statins in Alzheimers Disease: II Review of Human Trials
and Recommendations. Arch Neurol 2011;68(11):1385-1392.
16. Snitz BE, OMeara ES, Carlson MC, Arnold AM, Ives DG, Rapp SR, etal; Ginkgo Evaluation of Memory (GEM)
StudyInvestigators. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA
2009;302(24):2663-70.
17. Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, et al; GuidAge Study Group. Long-term use of
standardised Ginkgo biloba extract for the prevention of Alzheimers disease (Guid Age): a randomised placebocontrolled trial. Lancet Neurol 2012;11(10):851-9.

36